Terapia con Attinio-225 per il tumore neuroendocrino presso un centro accreditato JCI & ESMO

• Terapia con Actinio-225
• Esame di follow-up
• Esami del sangue

• Trasferimento aeroporto-clinica-aeroporto

The Actinium-225 (Ac-225) DOTA Alpha Neuroendocrine Premium Program is an advanced precision therapy developed for patients with progressive, metastatic, or treatment-resistant neuroendocrine tumors.

This treatment uses Actinium-225, a highly potent alpha-emitting isotope, attached to a targeting molecule that binds specifically to neuroendocrine tumor cells. Once absorbed into the cancer cell, Actinium-225 releases powerful radiation directly inside the tumor, destroying it from within. Because alpha radiation travels only a very short distance, surrounding healthy tissue is largely protected.

Prior to therapy, a previously performed DOTA PET scan is carefully reviewed and consulted in order to confirm sufficient receptor expression and determine whether the patient is suitable for treatment. The therapy decision is based on this molecular imaging evaluation, ensuring an individualized and targeted treatment approach.

The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings over two decades of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols.

The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability.

The treatment package includes medical consultation, comprehensive blood testing, renal evaluation when indicated, administration of Actinium-225 DOTA therapy, and structured post-treatment follow-up by a nuclear medicine specialist.

The recommended stay is approximately four days per treatment cycle, including arrival and departure. This duration applies provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety.

For patient comfort, we offer cost-efficient partner hotels located near the hospital, providing daily shuttle service between the hotel and the medical center, ensuring convenient and stress-free logistics during treatment.

This program offers a next-generation molecular therapy option for complex neuroendocrine cancer cases within a controlled and internationally coordinated clinical framework.

• Coordinatore medico personale
• Organizzazione dei viaggi medici — prenotazione di biglietti aerei e camere d'albergo a prezzi speciali per i partner
• Tutela degli interessi dei pazienti durante il viaggio medico